TY - JOUR T1 - Role of 18F-FDG-PET/CT in patients with differentiated thyroid cancer with biochemical incomplete or indeterminate response to treatment JO - Endocrinología, Diabetes y Nutrición T2 - AU - Abelleira,Erika AU - García Falcone,María Gabriela AU - Bueno,Fernanda AU - Pitoia,Fabián SN - 25300164 M3 - 10.1016/j.endinu.2020.02.007 DO - 10.1016/j.endinu.2020.02.007 UR - https://www.elsevier.es/es-revista-endocrinologia-diabetes-nutricion-13-articulo-role-18f-fdg-pet-ct-in-patients-with-S2530016420301099 AB - ObjectivesTo assess the value of 18F-FDG-PET/CT for detecting recurrent/persistent disease in patients with biochemical incomplete (BIR) or indeterminate response (IR) and to assess the impact of 18F-FDG-PET/CT on the therapeutic management of these patients. MethodsThe study included patients with BIR, in whom 18F-FDG PET/CT was used within the diagnostic algorithm from our database. Patients with IR referred to our hospital with the 18F-FDG PET/CT already performed were also enrolled. All patients had neck ultrasonography with no structural changes. A change in therapeutic approach was defined as repeat surgery; administration of external beam radiotherapy; and/or the start of systemic therapy. ResultsSixty patients (85% women) aged 18–86 years were enrolled in this retrospective study. Of these, 75% had BIR and 25% IR. Increased FDG uptake suggesting locoregional lesions was seen in 40% of patients. Sensitivity, specificity, and diagnostic accuracy of 18F-FDG PET/CT to detect local disease were 95%, 87.5% and 90% respectively. The therapeutic approach was modified in 50% of patients with locoregional lesions. ConclusionsOur study confirmed that 18F-FDG-PET/CT is a useful tool for detecting locoregional recurrence in thyroid cancer patients with BIR or IR with conflicting findings in standard diagnostic procedures. In 50% of patients with locoregional lesions, there was an immediate change in the treatment approach. ER -